There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Werewolf Therapeutics (HOWL – Research Report), Oric Pharmaceuticals (ORIC – Research Report) and Acadia ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...
Werewolf Therapeutics (NASDAQ:HOWL) has made great progress thus far in advancing its IL-2 drug known as WTX-124 for the treatment of patients with advanced or metastatic solid tumors. It has an ...
Werewolf Therapeutics, Inc. is an early-stage biotech focusing on cytokine therapy for cancer treatment. The Pipeline update includes positive results for WTX-124 in clinical trials and promising data ...
Investors might want to bet on Werewolf Therapeutics, Inc. (HOWL), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Director Luke Evnin of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) recently sold a total of 199,356 shares of common stock in three separate transactions, netting approximately $251,348. The sale comes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback